Oaktree creates third life sciences SPAC, following success with Hims & Hers and Alvotech
Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after previously using blank checks to take public
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.